What is the treatment for Pelvic Inflammatory Disease (PID) caused by gonorrhea infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Pelvic Inflammatory Disease (PID) from Gonorrhea Infection

The recommended treatment for PID caused by gonorrhea infection consists of ceftriaxone 250 mg IM as a single dose plus doxycycline 100 mg orally twice daily for 14 days, with the addition of metronidazole 500 mg orally twice daily for 14 days to provide anaerobic coverage. 1

Outpatient Treatment Regimens

For patients with mild to moderate PID who can be treated as outpatients, the CDC recommends the following regimens:

Regimen A

  • Ceftriaxone 250 mg IM in a single dose 1, 2
  • PLUS
  • Doxycycline 100 mg orally twice daily for 14 days
  • WITH
  • Metronidazole 500 mg orally twice daily for 14 days

Alternative Regimen B

  • Cefoxitin 2 g IM in a single dose 1, 3
  • PLUS
  • Probenecid 1 g orally in a single dose
  • PLUS
  • Doxycycline 100 mg orally twice daily for 14 days
  • WITH
  • Metronidazole 500 mg orally twice daily for 14 days

Inpatient Treatment Regimens

For patients with severe PID requiring hospitalization, the CDC recommends:

Regimen A

  • Cefoxitin 2 g IV every 6 hours OR Cefotetan 2 g IV every 12 hours 1
  • PLUS
  • Doxycycline 100 mg IV or orally every 12 hours

Regimen B

  • Clindamycin 900 mg IV every 8 hours 4, 1
  • PLUS
  • Gentamicin loading dose IV or IM (2 mg/kg) followed by maintenance dose (1.5 mg/kg) every 8 hours

Parenteral therapy should be continued for at least 24 hours after clinical improvement, then complete a 14-day course with oral antibiotics.

Indications for Hospitalization

Patients should be hospitalized for PID treatment if they have:

  • Severe illness with high fever
  • Nausea/vomiting preventing oral medication
  • Suspected tubo-ovarian abscess
  • Pregnancy
  • Failed outpatient therapy
  • Inability to follow or tolerate outpatient regimen 1

Important Clinical Considerations

  1. Dual pathogen coverage: Since PID is often polymicrobial, treatment must cover both N. gonorrhoeae and C. trachomatis, even when only gonorrhea is confirmed 1, 5

  2. Anaerobic coverage: Metronidazole is added to provide coverage against anaerobic bacteria and bacterial vaginosis, which are frequently associated with PID 1, 6

  3. Partner treatment: Sex partners should be evaluated and treated empirically for both C. trachomatis and N. gonorrhoeae to prevent reinfection 1

  4. Follow-up: Patients should be reassessed within 72 hours of starting treatment. If no clinical improvement is seen, hospitalization for parenteral therapy should be considered 1

  5. Retesting: The CDC recommends retesting for C. trachomatis and N. gonorrhoeae approximately 3 months after treatment completion due to high rates of reinfection 1

Complications and Prevention

Untreated or inadequately treated PID can lead to serious complications including:

  • Infertility due to tubal scarring
  • Chronic pelvic pain
  • Ectopic pregnancy
  • Tubo-ovarian abscess formation 1, 6

Early and appropriate antibiotic therapy is essential to prevent these long-term sequelae. Screening for chlamydial and gonococcal infections in high-risk women can reduce PID incidence 6.

References

Guideline

Pelvic Inflammatory Disease Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Pelvic inflammatory disease (PID) from Chlamydia trachomatis versus PID from Neisseria gonorrhea: from clinical suspicion to therapy.

Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.